Phase 3 Peripheral Arterial Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have recently had a procedure to restore blood flow in a leg artery (below a certain point in the pelvis) due to artery blockages caused by plaque build-up, and this procedure happened within the last 10 days
- You meet at least one of the following risk factors: you received a synthetic (man-made) bypass graft during your procedure; you had a stent placed during your procedure; the blocked section of artery treated was longer than about 6 inches; you have had a previous leg artery procedure or amputation related to poor circulation; you have Type 2 diabetes that is treated with medication; you also have heart artery disease with symptoms (confirm with trial site for exact definition); you have chronic kidney disease (confirm with trial site for exact definition); or you are 75 years old or older
Who may not be able to join:
- You currently have a condition that requires you to take blood-thinning medication long-term, including a specific clotting disorder called triple positive antiphospholipid syndrome
- You have a known bleeding disorder, a very low platelet count, a history of bleeding in the brain not caused by injury, or certain known brain blood vessel conditions
- You have recently had a procedure to open blocked heart arteries (confirm with trial site for exact timeframe)
- For one specific group in the trial only: your kidneys are functioning at a very low level, or you are on dialysis, or you are expected to start dialysis within the next 12 weeks
- You have any other medical condition or treatment that the trial team believes would make it unsafe or unsuitable for you to participate for the full length of the study
- You have a known allergy or bad reaction to any of the study medications being tested in this trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Trial Management, Regeneron Pharmaceuticals
Phone: 844-734-6643
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Time-to-first occurrence of a major thrombotic vascular event, consisting of Acute Limb Ischemia (ALI), major amputation (above the ankle) of vascular etiology, Myocardial Infarction (MI), ischemic stroke, or Cardiovascular (CV) death; Time-to-first occurrence of International Society of Thrombosis and Hemostasis (ISTH) major or Clinically Relevant Non-major (CRNM) bleeding
Can't join this trial?
Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.